Hombach V, Braun V, Höpp H W, Gil-Sanchez D, Behrenbeck D W, Tauchert M, Hilger H H
Klin Wochenschr. 1981 Feb 2;59(3):123-33. doi: 10.1007/BF01477354.
In a total of 18 patients, 7 females and 11 male patients with ages ranging from 23 to 70 years (mean: 45.5 +/- 14.5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv. over 3 to 5 minutes. In 7 patients the pacing procedure could be repeated following ergometric exercise in order to evaluate the influence of a raised sympathetic tone on the conditions initiating paroxysmal tachycardias. At rest, atenolol prevented the pacing induced tachycardias (20 dysrhythmias in 18 patients) in 3/5 individuals with Wolff-Parkinson-White (WPW)-syndrome, in 4/6 cases with atrial tachycardias, in 4/6 patients presenting atrial flutter, in 2/2 cases developing AV-nodal tachycardias and in 1/1 individual with ventricular tachycardia. Thus, in 13 out of 19 (68%) supraventricular dysrhythmias patients benefitted from atenolol by preventing or controlling the tachycardia. Ergometric exercise changed the tachycardia or echo zone in 5/8 arrhythmias after betablockade when compared to the controls before administration of atenolol (3/5 improvement by narrowing of the tach- or echo zone, 1/5 prevention of tachycardia, 1/5 impairment due to widening of the tachycardia zone). Considering only the prevention of tachycardias, the antiarrhythmic potency of atenolol was improved in one patient with pacing induced flutter and impaired in one individual with a WPW syndrome, by ergometric exercise. These results suggest that atenolol seems to provide a good antiarrhythmic action, especially in supraventricular tachycardias, and that an increased sympathetic tone during exercise may modify the antidysrhythmic strength of betablockade.
共有18例患者,其中7例女性,11例男性,年龄在23至70岁之间(平均:45.5±14.5),在使用心脏选择性β受体阻滞剂阿替洛尔进行β受体阻滞剂治疗前后,进行了诊断性希氏束研究,包括程控心房和心室起搏以诱发心动过速,阿替洛尔静脉注射剂量为5mg,在3至5分钟内给药。7例患者在进行运动试验后可重复起搏程序,以评估交感神经张力升高对阵发性心动过速起始条件的影响。静息时,阿替洛尔在3/5例预激综合征(WPW)患者、4/6例房性心动过速患者、4/6例心房扑动患者、2/2例房室结性心动过速患者和1/1例室性心动过速患者中预防了起搏诱发的心动过速(18例患者中出现20次心律失常)。因此,在19例(68%)室上性心律失常患者中,有13例通过预防或控制心动过速从阿替洛尔中获益。与阿替洛尔给药前的对照组相比,运动试验使β受体阻滞剂治疗后5/8例心律失常的心动过速或折返区发生改变(3/5例通过心动过速或折返区变窄得到改善,1/5例预防了心动过速,1/5例因心动过速区增宽而受损)。仅考虑心动过速的预防,运动试验使1例起搏诱发扑动患者的阿替洛尔抗心律失常效力提高,1例WPW综合征患者的效力降低。这些结果表明,阿替洛尔似乎具有良好的抗心律失常作用,尤其是在室上性心动过速中,并且运动期间交感神经张力增加可能会改变β受体阻滞剂的抗心律失常强度。